Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
Primary Purpose
Preterm Premature Rupture of Membranes, Pregnant State
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Pomgranate pills
Placebo pills
Sponsored by
About this trial
This is an interventional treatment trial for Preterm Premature Rupture of Membranes focused on measuring Preterm premature rupture of membranes, pomgranate, oxidative stress, pregnant women with Preterm premature rupture of membranes
Eligibility Criteria
Inclusion Criteria:
- pregnancy
- singleton pregnancy
- preterm premature rupture of membranes
- gestational age > 24Wks
Exclusion Criteria:
- gestational age > 24wks
- fetal anomalies
Sites / Locations
- Rambam Health Care CampusRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Pomegranate pills
placebo pills
Arm Description
treatment with pomgranate pills to women suffering preterm premature rupture of membranes
treatment with placebo to women with preterm premature rupture of membranes
Outcomes
Primary Outcome Measures
Oxidative Stress
Serum lipid peroxidation
Serum lipids peroxidation
Lipid peroxide formation
Paraoxonase activity measurements
Secondary Outcome Measures
Obstetrical outcomes
Apgar score
cord PH
cord CRP levels
Full Information
NCT ID
NCT01584323
First Posted
April 16, 2012
Last Updated
April 22, 2012
Sponsor
Rambam Health Care Campus
1. Study Identification
Unique Protocol Identification Number
NCT01584323
Brief Title
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
Official Title
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
Study Type
Interventional
2. Study Status
Record Verification Date
April 2012
Overall Recruitment Status
Unknown status
Study Start Date
April 2012 (undefined)
Primary Completion Date
April 2015 (Anticipated)
Study Completion Date
May 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rambam Health Care Campus
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this study the investigators sought to determine the effects of Pomegranate (Natural pomegranate polyphenol (P. granatum L) extract) :
On the maternal and fetal oxidative stress and inflammation associated with PPROM.
On the time interval from PPROM to delivery and on fetal Ph and apger score.
Detailed Description
Preterm premature rupture of membranes is the rupture of membranes during pregnancy before 37 weeks' gestation. It occurs in 3 percent of pregnancies and is the cause of approximately one third of preterm deliveries. It can lead to significant perinatal morbidity, including respiratory distress syndrome, neonatal sepsis, umbilical cord prolapse, placental abruption, and fetal death.(ref) It increases the risk of prematurity and leads to a number of other perinatal and neonatal complications, including a 1 to 2 percent risk of fetal death.(2) The latent period, which is the time from membrane rupture until delivery, generally is inversely proportional to the gestational age at which PROM occurs. For example, one large study (3) of patients at term revealed that 95 percent of patients delivered within approximately one day of PROM, whereas an analysis of studies(4) evaluating patients with preterm PROM between 16 and 26 weeks' gestation determined that 57 percent of patients delivered within one week, and 22 percent had a latent period of four weeks Numerous risk factors are associated with preterm premature rupture of membrane, lower socioeconomic status, are smokers, have a history of sexually transmitted infections, have had a previous preterm delivery, have vaginal bleeding, or have uterine distension (e.g., polyhydramnios, choriodecidual infection, in many cases the PPROM is associated inflammatory process and increased oxidative stress. Intrauterine inflammation may be associated with, fetal injury preterm birth, low birth weight, and cerebral palsy (5,6,7,8,9). While treatment for PPROM Includes antibiotics it does not aimed to cope with the increased oxidative stress and inflammation that are associated with PPROM and are thought to play important role in the fetal injury Pomegranate juice contains a high concentration of vitamins (C, B1, B2, B3, B5), potassium, Magnesium, Zinc and is a good source for polyphenols (10). Polyphenols molecules have been found to possess antioxidant properties as well as effects on gene expression (11). Recent studies indicate that among foods that contain polyphenols, juice extracted from the pomegranate has the highest concentration of measurable polyphenols (12,13). Pomegranates have shown activity against the cytokine NF-κB and the MAP kinases JNK and ERK, which are critical steps in the cascade of events leading to inflammatory response The NF- κB pathway is activated in response to bacterial infection, and this may explain the effects against bacterial infection (14). Juice consumption may also inhibit viral infection (15).
In a rat animal model pomegranate juice that was given to the dams during pregnancy and lactation period was found as neuroprotective agent to the neonatal mouse brain.(16). Recently Tuuli et al published abstract at the annual meeting of the society of maternal fetal medicine 2011, demonstrating that pomefranate juice (8 oz a day) supplement for the last two weeks to pregnancy, reduced significantly the placental oxidative stress associated with delivery compared to control.
Enhancing the activity or the availability of antioxidants may modulate the inflammatory response associated with PPROM, thereby reducing oxidative stress and the risk to the fetus. In this study we sought to determine the effects of Pomegranate 1. on the maternal and fetal oxidative stress and inflammation associated with PPROM 2. On the time interval from PPROM to delivery and on fetal Ph and apger score.
Study protocol:
All the women admitted with PPROM will receive the usual protocol of the department (Penibrin for two days and Erythromycin for five days)
After signing approval to participate in the study, blood will be drawn for determining the oxidative stress markers (will be analyzed after delivery). The patient will continue the department routine PPROM protocol.
After admission the women will be divided to two groups. One group will receive The POMx pomegranate 1,000 mg capsule a day. The other group will receive placebo. Both groups will receive regiments for a maximum of two weeks or until they deliver if occurs beforehand.
The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)
The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy.
During pregnancy:
The patient will continue their usual PPROM protocol.
After delivery After delivery of the baby 1.umbilical blood will be drawn from the umbilical cord and maternal serum for oxidative stress markers Ph and C-reactive protein 2. Histological evaluation of the placenta for inflammation
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Premature Rupture of Membranes, Pregnant State
Keywords
Preterm premature rupture of membranes, pomgranate, oxidative stress, pregnant women with Preterm premature rupture of membranes
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Pomegranate pills
Arm Type
Active Comparator
Arm Description
treatment with pomgranate pills to women suffering preterm premature rupture of membranes
Arm Title
placebo pills
Arm Type
Placebo Comparator
Arm Description
treatment with placebo to women with preterm premature rupture of membranes
Intervention Type
Dietary Supplement
Intervention Name(s)
Pomgranate pills
Intervention Description
Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before
The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo pills
Intervention Description
The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
Primary Outcome Measure Information:
Title
Oxidative Stress
Description
Serum lipid peroxidation
Serum lipids peroxidation
Lipid peroxide formation
Paraoxonase activity measurements
Time Frame
Measurments will be first taken at the day of admission (for the mother) and will be assessed immediatly after delivery (mother and newborn)
Secondary Outcome Measure Information:
Title
Obstetrical outcomes
Description
Apgar score
cord PH
cord CRP levels
Time Frame
Measurments will be first taken at the day of admission (for the mother) and will be assessed immediatly after delivery (mother and newborn)
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
17 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
pregnancy
singleton pregnancy
preterm premature rupture of membranes
gestational age > 24Wks
Exclusion Criteria:
gestational age > 24wks
fetal anomalies
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ido Solt, M.D
Organizational Affiliation
Rambam Health Care Campus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rambam Health Care Campus
City
Haifa
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuval Ginsberg, M.D
Phone
+972502061395
Email
y_ginsberg@rambam.health.gov.il
First Name & Middle Initial & Last Name & Degree
Ido Solt, M.D
Phone
+972502062681
Email
I_solt@rambam.health.gov.il
12. IPD Sharing Statement
Learn more about this trial
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
We'll reach out to this number within 24 hrs